Drugs / MM-093
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00458146 | Feb 2007 → ? | rheumatoid arthritis | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00147329 | Sep 2005 → Jul 2006 | psoriasis | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00105976 | Feb 2005 → ? | rheumatoid arthritis | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00444743 Comparator | Feb 2007 → Nov 2008 | uveitis | Merrimack Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MM-093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00444743 ↗ |
| Modality | Protein / enzyme biologic | “MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein (AFP).” NCT00105976 ↗ |
| Route | Subcutaneous | “60 mg, administered subcutaneously, weekly” NCT00444743 ↗ |